Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06063746 | Compassionate Use of Vidutolimod | no longer available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Jan 8, 2026 | clinicaltrials |
| NCT04489433 | Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 18, 2025 | clinicaltrials |
| NCT06590480 | An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma(RPL-EAP-001) | no longer available | — | — | Replimune, Inc.INDUSTRY | 0 | Dec 18, 2025 | clinicaltrials |
| NCT03593499 | Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401 | no longer available | — | — | BiogenINDUSTRY | 0 | May 31, 2025 | clinicaltrials |
| NCT04544202 | Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 12, 2024 | clinicaltrials |
| NCT04289155 | Individual Patient Compassionate Use of GX-I7 | no longer available | — | — | Genexine, Inc.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT03554434 | An Expanded Access Program for AM0010 (Pegilodecakin) | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Mar 2, 2020 | clinicaltrials |
| NCT02297529 | Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma | no longer available | — | — | AmgenINDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT02083484 | Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) | no longer available | — | — | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 26, 2018 | clinicaltrials |
| NCT03311542 | Expanded Access for Pembrolizumab (MK-3475) | no longer available | — | — | Center Trials & TreatmentOTHER | 4 | Jan 10, 2018 | clinicaltrials |
| NCT02416232 | Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma | no longer available | — | — | GlaxoSmithKlineINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT02186249 | Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma(CheckMate218) | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 2 | Feb 8, 2017 | clinicaltrials |
| NCT02147951 | Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma | no longer available | — | — | AmgenINDUSTRY | 1 | Mar 1, 2016 | clinicaltrials |
| NCT01728051 | Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver | no longer available | — | — | Delcath Systems Inc.INDUSTRY | 1 | Oct 23, 2013 | clinicaltrials |
| NCT00495066 | Compassionate Use Trial for Unresectable Melanoma With Ipilimumab | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 1 | Jun 3, 2013 | clinicaltrials |
| NCT01005537 | Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma | no longer available | — | — | Fred Hutchinson Cancer CenterOTHER | 0 | Aug 6, 2010 | clinicaltrials |
| NCT00584493 | Treatment Use Study for Advanced Melanoma. | no longer available | — | — | PfizerINDUSTRY | 0 | Dec 14, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Jan 8, 2026source: clinicaltrials